BRPI0719570A2 - Quinazolinas substituídas - Google Patents

Quinazolinas substituídas Download PDF

Info

Publication number: BRPI0719570A2
Authority: BR; Brazil
Prior art keywords: group; compound according; alkyl; anagrelide; compound
Prior art date: 2006-11-28

Application number

BRPI0719570-2A

Other languages

English (en)

Portuguese (pt)

Inventor

Richard Franklin

Bernard Golding

Original Assignee

Shire Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-28

Filing date

2007-11-19

Publication date

2013-12-10

2007-11-19 Application filed by Shire Llc filed Critical Shire Llc

2013-12-10 Publication of BRPI0719570A2 publication Critical patent/BRPI0719570A2/pt

Links

150000001875 compounds Chemical class 0.000 claims abstract description 98
238000011282 treatment Methods 0.000 claims abstract description 20
125000000217 alkyl group Chemical group 0.000 claims description 30
238000000034 method Methods 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 21
239000003814 drug Substances 0.000 claims description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
229910052739 hydrogen Inorganic materials 0.000 claims description 19
241000282414 Homo sapiens Species 0.000 claims description 18
229910052799 carbon Inorganic materials 0.000 claims description 18
125000005843 halogen group Chemical group 0.000 claims description 16
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
125000004093 cyano group Chemical group *C#N 0.000 claims description 13
239000001257 hydrogen Substances 0.000 claims description 13
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 11
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
125000003342 alkenyl group Chemical group 0.000 claims description 11
201000010099 disease Diseases 0.000 claims description 11
239000012453 solvate Substances 0.000 claims description 11
239000000460 chlorine Substances 0.000 claims description 10
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
125000000304 alkynyl group Chemical group 0.000 claims description 9
229910052801 chlorine Inorganic materials 0.000 claims description 9
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 8
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
229910052794 bromium Inorganic materials 0.000 claims description 8
125000000753 cycloalkyl group Chemical group 0.000 claims description 8
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
239000011737 fluorine Substances 0.000 claims description 8
229910052731 fluorine Inorganic materials 0.000 claims description 8
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
208000007536 Thrombosis Diseases 0.000 claims description 7
230000000903 blocking effect Effects 0.000 claims description 7
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
125000001188 haloalkyl group Chemical group 0.000 claims description 7
239000011630 iodine Substances 0.000 claims description 7
229910052740 iodine Inorganic materials 0.000 claims description 7
125000002837 carbocyclic group Chemical group 0.000 claims description 6
230000006870 function Effects 0.000 claims description 6
125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 5
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 5
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 5
238000006243 chemical reaction Methods 0.000 claims description 5
230000002503 metabolic effect Effects 0.000 claims description 5
238000006241 metabolic reaction Methods 0.000 claims description 5
230000009467 reduction Effects 0.000 claims description 5
238000006467 substitution reaction Methods 0.000 claims description 5
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 4
125000004181 carboxyalkyl group Chemical group 0.000 claims description 4
238000007911 parenteral administration Methods 0.000 claims description 4
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 2
125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
238000011200 topical administration Methods 0.000 claims description 2
125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
125000001309 chloro group Chemical group Cl* 0.000 claims 2
SYKNUAWMBRIEKB-UHFFFAOYSA-N [Cl].[Br] Chemical compound [Cl].[Br] SYKNUAWMBRIEKB-UHFFFAOYSA-N 0.000 claims 1
229910021645 metal ion Inorganic materials 0.000 claims 1
229960001694 anagrelide Drugs 0.000 abstract description 73
OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 abstract description 62
230000000694 effects Effects 0.000 abstract description 32
210000001772 blood platelet Anatomy 0.000 abstract description 21
230000015572 biosynthetic process Effects 0.000 abstract description 16
230000002526 effect on cardiovascular system Effects 0.000 abstract description 15
230000001976 improved effect Effects 0.000 abstract description 12
208000014767 Myeloproliferative disease Diseases 0.000 abstract description 10
230000002401 inhibitory effect Effects 0.000 abstract description 10
230000002829 reductive effect Effects 0.000 abstract description 10
KJMFQJFNQYWQAV-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinazoline Chemical class C1=NC=NC2=C(NC=N3)C3=CC=C21 KJMFQJFNQYWQAV-UHFFFAOYSA-N 0.000 abstract description 3
-1 anagrelide compound Chemical class 0.000 description 20
229940079593 drug Drugs 0.000 description 15
230000005764 inhibitory process Effects 0.000 description 14
125000004432 carbon atom Chemical group C* 0.000 description 12
KAXTUTDKZVOONF-UHFFFAOYSA-N 6,7-Dichloro-3-hydroxy-1,5 dihydro-imidazo[2,1-b]quinazolin-2-one Chemical compound N1=C2NC(=O)C(O)N2CC2=C1C=CC(Cl)=C2Cl KAXTUTDKZVOONF-UHFFFAOYSA-N 0.000 description 11
238000000338 in vitro Methods 0.000 description 10
239000000203 mixture Substances 0.000 description 10
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
239000002207 metabolite Substances 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
208000032027 Essential Thrombocythemia Diseases 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
208000035475 disorder Diseases 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
238000009472 formulation Methods 0.000 description 7
125000001183 hydrocarbyl group Chemical group 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
230000037396 body weight Effects 0.000 description 6
230000000052 comparative effect Effects 0.000 description 6
239000002570 phosphodiesterase III inhibitor Substances 0.000 description 6
230000003389 potentiating effect Effects 0.000 description 6
230000002411 adverse Effects 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
229910052751 metal Chemical group 0.000 description 5
239000002184 metal Chemical group 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
230000009471 action Effects 0.000 description 4
230000002744 anti-aggregatory effect Effects 0.000 description 4
210000003494 hepatocyte Anatomy 0.000 description 4
230000004060 metabolic process Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000002342 ribonucleoside Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000001732 thrombotic effect Effects 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 3
102000004316 Oxidoreductases Human genes 0.000 description 3
108090000854 Oxidoreductases Proteins 0.000 description 3
206010033557 Palpitations Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
239000001177 diphosphate Substances 0.000 description 3
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 3
235000011180 diphosphates Nutrition 0.000 description 3
239000010408 film Substances 0.000 description 3
238000010579 first pass effect Methods 0.000 description 3
229960001330 hydroxycarbamide Drugs 0.000 description 3
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
230000009466 transformation Effects 0.000 description 3
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
ULNVBRUIKLYGDF-UHFFFAOYSA-N 1,3-bis(4-methylphenyl)thiourea Chemical compound C1=CC(C)=CC=C1NC(=S)NC1=CC=C(C)C=C1 ULNVBRUIKLYGDF-UHFFFAOYSA-N 0.000 description 2
IGMDPBNGNRHCRW-UHFFFAOYSA-N 6,7-dichloro-3,3-dimethyl-5,10-dihydroimidazo[2,1-b]quinazolin-2-one Chemical compound C1=CC(Cl)=C(Cl)C2=C1NC1=NC(=O)C(C)(C)N1C2 IGMDPBNGNRHCRW-UHFFFAOYSA-N 0.000 description 2
206010007559 Cardiac failure congestive Diseases 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical group F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 2
108010081348 HRT1 protein Hairy Chemical group 0.000 description 2
102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
208000005485 Thrombocytosis Diseases 0.000 description 2
102000010861 Type 3 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
108010037543 Type 3 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
229960003555 anagrelide hydrochloride Drugs 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
208000002173 dizziness Diseases 0.000 description 2
238000001035 drying Methods 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
239000000499 gel Substances 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
150000002431 hydrogen Chemical class 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
125000002768 hydroxyalkyl group Chemical group 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
229960003574 milrinone Drugs 0.000 description 2
PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
238000010534 nucleophilic substitution reaction Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
208000012284 reactive thrombocytosis Diseases 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000000844 transformation Methods 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
125000006024 2-pentenyl group Chemical group 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
125000006041 3-hexenyl group Chemical group 0.000 description 1
WYQHLULFNFNASP-UHFFFAOYSA-N 3h-imidazo[2,1-b]quinazolin-2-one Chemical class C1=CC=CC2=NC3=NC(=O)CN3C=C21 WYQHLULFNFNASP-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
YLFXXKJQBOJJIX-UHFFFAOYSA-N 6,7-dichloro-5,10-dihydro-3h-imidazo[2,1-b]quinazolin-2-one;hydrate;hydrochloride Chemical compound O.Cl.N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 YLFXXKJQBOJJIX-UHFFFAOYSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
206010048610 Cardiotoxicity Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000005230 Leg Ulcer Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028400 Mutagenic effect Diseases 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
102100034195 Thrombopoietin Human genes 0.000 description 1
206010043647 Thrombotic Stroke Diseases 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
208000017733 acquired polycythemia vera Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
229940060238 agrylin Drugs 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000006502 antiplatelets effects Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000007214 atherothrombosis Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
231100000259 cardiotoxicity Toxicity 0.000 description 1
231100000060 cardiovascular toxicity Toxicity 0.000 description 1
230000007681 cardiovascular toxicity Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000007810 chemical reaction solvent Substances 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
101150055214 cyp1a1 gene Proteins 0.000 description 1
230000002435 cytoreductive effect Effects 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000005549 deoxyribonucleoside Substances 0.000 description 1
230000005595 deprotonation Effects 0.000 description 1
238000010537 deprotonation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000011833 dog model Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
239000002359 drug metabolite Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229960000972 enoximone Drugs 0.000 description 1
ZJKNESGOIKRXQY-UHFFFAOYSA-N enoximone Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(C)NC(=O)N1 ZJKNESGOIKRXQY-UHFFFAOYSA-N 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
ARFLASKVLJTEJD-SCSAIBSYSA-N ethyl (2r)-2-bromopropanoate Chemical compound CCOC(=O)[C@@H](C)Br ARFLASKVLJTEJD-SCSAIBSYSA-N 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000013265 extended release Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000003517 fume Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
230000010247 heart contraction Effects 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
230000010224 hepatic metabolism Effects 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
231100000003 human carcinogen Toxicity 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000007915 intraurethral administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000011418 maintenance treatment Methods 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
231100000243 mutagenic effect Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000008693 nausea Effects 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
208000037244 polycythemia vera Diseases 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000001144 postural effect Effects 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
208000003476 primary myelofibrosis Diseases 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
239000000779 smoke Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
125000003003 spiro group Chemical group 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
230000009044 synergistic interaction Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
230000003582 thrombocytopenic effect Effects 0.000 description 1
HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
238000004448 titration Methods 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0719570-2A 2006-11-28 2007-11-19 Quinazolinas substituídas BRPI0719570A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0623750.7		2006-11-28
GBGB0623750.7A GB0623750D0 (en)	2006-11-28	2006-11-28	Substituted quinazolines
PCT/GB2007/050697 WO2008065444A2 (en)	2006-11-28	2007-11-19	Substituted quinazolines

Publications (1)

Publication Number	Publication Date
BRPI0719570A2 true BRPI0719570A2 (pt)	2013-12-10

Family

ID=37671460

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0719570-2A BRPI0719570A2 (pt)	2006-11-28	2007-11-19	Quinazolinas substituídas

Country Status (14)

Country	Link
EP (1)	EP2099802A2 (es)
JP (1)	JP2010511030A (es)
KR (1)	KR20090094268A (es)
CN (1)	CN101558071B (es)
AR (1)	AR064002A1 (es)
AU (1)	AU2007327047B2 (es)
BR (1)	BRPI0719570A2 (es)
CA (1)	CA2670123A1 (es)
EA (1)	EA018259B1 (es)
GB (1)	GB0623750D0 (es)
IL (1)	IL198809A0 (es)
MX (1)	MX2009005579A (es)
TW (1)	TW200838537A (es)
WO (1)	WO2008065444A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0808944D0 (en) *	2008-05-16	2008-06-25	Shire Llc	Substituted quinazolines
GB2462022B (en)	2008-06-16	2011-05-25	Biovascular Inc	Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
GB0822970D0 (en) *	2008-12-17	2009-01-21	Shire Llc	Process for the preparation of anagrelide and analogues
GB201004495D0 (en)	2010-03-18	2010-05-05	Shire Llc	Subtituted quinazolines
GB201017783D0 (en)	2010-10-21	2010-12-01	Shire Llc	Process for the preparation of anagrelide and analogues thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7807507A (nl) *	1977-07-25	1979-01-29	Hoffmann La Roche	Tricyclische verbindingen.
CA1131631A (en) *	1979-06-20	1982-09-14	Madhukar S. Chodnekar	Quinazoline derivatives and pharmaceutical preparations
ZA803535B (en) *	1979-06-20	1981-06-24	Hoffmann La Roche	Novel quinazoline derivatives and pharmaceutical preparations
EA010871B1 (ru) *	2003-01-23	2008-12-30	Шир Холдингз Аг	Трансдермальные составы и способы лечения тромбоцитемии
US20060030574A1 (en) *	2004-08-04	2006-02-09	Shire Holdings Ag	Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US7700608B2 (en) *	2004-08-04	2010-04-20	Shire Holdings Ag	Quinazoline derivatives and their use in the treatment of thrombocythemia

2006
- 2006-11-28 GB GBGB0623750.7A patent/GB0623750D0/en not_active Ceased
2007
- 2007-11-19 KR KR1020097011682A patent/KR20090094268A/ko not_active Ceased
- 2007-11-19 JP JP2009538792A patent/JP2010511030A/ja active Pending
- 2007-11-19 MX MX2009005579A patent/MX2009005579A/es unknown
- 2007-11-19 AU AU2007327047A patent/AU2007327047B2/en not_active Expired - Fee Related
- 2007-11-19 CN CN2007800442429A patent/CN101558071B/zh not_active Expired - Fee Related
- 2007-11-19 EA EA200900740A patent/EA018259B1/ru not_active IP Right Cessation
- 2007-11-19 WO PCT/GB2007/050697 patent/WO2008065444A2/en not_active Ceased
- 2007-11-19 CA CA002670123A patent/CA2670123A1/en not_active Abandoned
- 2007-11-19 BR BRPI0719570-2A patent/BRPI0719570A2/pt not_active IP Right Cessation
- 2007-11-19 EP EP07824909A patent/EP2099802A2/en not_active Withdrawn
- 2007-11-27 TW TW096145020A patent/TW200838537A/zh unknown
- 2007-11-28 AR ARP070105272A patent/AR064002A1/es unknown
2009
- 2009-05-19 IL IL198809A patent/IL198809A0/en unknown

Also Published As

Publication number	Publication date
KR20090094268A (ko)	2009-09-04
AU2007327047A1 (en)	2008-06-05
WO2008065444A3 (en)	2008-07-31
WO2008065444B1 (en)	2008-10-09
TW200838537A (en)	2008-10-01
EA200900740A1 (ru)	2010-02-26
CN101558071B (zh)	2013-04-24
EP2099802A2 (en)	2009-09-16
WO2008065444A2 (en)	2008-06-05
AR064002A1 (es)	2009-03-04
CA2670123A1 (en)	2008-06-05
MX2009005579A (es)	2009-08-12
JP2010511030A (ja)	2010-04-08
EA018259B1 (ru)	2013-06-28
GB0623750D0 (en)	2007-01-10
CN101558071A (zh)	2009-10-14
AU2007327047B2 (en)	2012-08-30
IL198809A0 (en)	2010-02-17

Publication	Publication Date	Title
US20110071173A1 (en)	2011-03-24	Imidazoquinazoline derivatives as anagrelide analogues for the treatment of myeloprolific diseases and thrombotic diseases
BRPI0719570A2 (pt)	2013-12-10	Quinazolinas substituídas
US20110152298A1 (en)	2011-06-23	Imidazo [2,1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents
US20110071171A1 (en)	2011-03-24	2h- pyrimido [2, 1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents
US20110065714A1 (en)	2011-03-17	Substituted quinazolines
US20110130405A1 (en)	2011-06-02	Substituted quinazolines as blood platelet lowering agents
US20110071174A1 (en)	2011-03-24	Substituted quinazolines
US20110086851A1 (en)	2011-04-14	Substituted quinazolines and their uses for myeoloprolific and thrombotic diseases
US7910597B2 (en)	2011-03-22	Substituted quinazolines
US20110071172A1 (en)	2011-03-24	Substituted quinazolines as blood platelet lowering agents

Legal Events

Date	Code	Title	Description
2014-09-30	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2015-03-24	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2282 DE 30/09/2014.